ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM) patients at the European Society for Medical Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona, Spain..

瑞士ROOT——（商业新闻短讯）——Novocure（纳斯达克：NVCR）今天宣布，它将在2024年9月13日至17日于西班牙巴塞罗那举行的欧洲肿瘤内科学会（ESMO）大会上，对其肿瘤治疗领域（TTFields）治疗的使用情况和新诊断的胶质母细胞瘤（ndGBM）患者的生存结果进行现实分析。。

The results of the real-world analysis suggest higher TTFields therapy device usage is significantly associated with improved survival outcomes in a broad population of ndGBM patients.

现实世界的分析结果表明，更高的TTFields治疗设备使用率与广泛的ndGBM患者的生存结果显着相关。

Novocure’s ESMO 2024 Data Presentation Details:

Novocure的ESMO 2024数据演示详情：

Poster #459: Association of Tumor Treating Fields Device Usage with Survival in Newly Diagnosed GBM: A Real-World Analysis of Patients in the US

海报#459：肿瘤治疗领域设备使用与新诊断GBM患者生存率的关系：美国患者的现实世界分析

Authors: Jennifer M. Connelly, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, United States; Santiago Cabezas-Camarero, Department of Medical Oncology, Hospital Universitario Clínico San Carlos (IdISSC), Madrid, Spain; Nick Avgeropoulos, Novocure, Inc., Portsmouth, NH, United States; Patrick Conlon, Novocure, Inc., Portsmouth, NH, United States; Gordon Chavez, Novocure, Inc., Portsmouth, NH, United States; Ori Farber, Novocure, Ltd., Haifa, Israel.

作者：美国威斯康星州密尔沃基威斯康星州医学院神经病学系Jennifer M.Connelly；圣地亚哥·卡贝扎斯·卡马雷罗，西班牙马德里圣卡洛斯大学医院肿瘤内科（IdISSC）；Nick Avgeropoulos，Novocure，Inc.，美国新罕布什尔州朴茨茅斯；Patrick Conlon，Novocure，Inc.，美国新罕布什尔州朴茨茅斯；Gordon Chavez，Novocure，Inc.，美国新罕布什尔州朴茨茅斯；Ori Farber，Novocure，Ltd.，以色列海法。

Date: Monday, September 16

日期：9月16日星期一

Abstracts are available on the ESMO website, esmo.org/meeting-calendar/esmo-congress-2024/programme.

摘要可在ESMO网站ESMO.org/meeting-calendar/ESMO-congress-2024/program上找到。

Novocure has also sponsored an ESMO Colloquium, The Role of Alternating Electric Fields in the Therapeutic Management of Patients with Advanced Non-Small Cell Lung Cancer, which will be held Monday, September 16, 13:00 - 14:30 CEST, in the Oviedo Auditorium, Hall 3.

Novocure还赞助了ESMO座谈会，即交流电场在晚期非小细胞肺癌患者治疗管理中的作用，该座谈会将于9月16日星期一13:00-14:30在CEST举行，地点为奥维耶多礼堂3号厅。

About Tumor Treating Fields

关于肿瘤治疗领域

Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells.

肿瘤治疗场（TTFields）是通过多种机制施加物理力杀死癌细胞的电场。TTFields不会显着影响健康细胞，因为它们具有与癌细胞不同的特性（包括分裂速率，形态和电特性）。

These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models.

这些多种不同的机制共同作用以靶向和杀死癌细胞。由于这些多机制作用，TTFields治疗可以在批准的适应症中添加到癌症治疗模式中，并且在临床前模型中与化疗，放疗，免疫检查点抑制或靶向治疗一起使用时，可以在实体瘤类型中显示出增强的效果。

TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com..

TTFields疗法提供了临床多功能性，有可能帮助解决一系列实体瘤的治疗挑战。要了解更多关于TTFields疗法及其对癌细胞的多方面影响，请访问tumortreatingfields.com。。

About Novocure

关于Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma.

Novocure是一家全球性肿瘤公司，致力于通过其创新疗法，肿瘤治疗领域的开发和商业化，延长一些最具侵袭性的癌症的生存期。Novocure的商业化产品在某些国家被批准用于治疗成人胶质母细胞瘤，恶性胸膜间皮瘤和胸膜间皮瘤患者。

Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer..

Novocure正在进行或完成临床试验，研究脑转移瘤，胃癌，胶质母细胞瘤，肝癌，非小细胞肺癌，胰腺癌和卵巢癌的肿瘤治疗领域。。

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X (Twitter)..

Novocure总部位于瑞士Root，全球足迹不断扩大，在朴茨茅斯、新罕布什尔州和东京设有区域运营中心，在以色列海法设有研究中心。有关该公司的更多信息，请访问Novocure.com，并在LinkedIn和X（推特）上关注@Novocure。。

Forward-Looking Statements

前瞻性声明

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts.

除了历史事实或现状声明外，本新闻稿可能还包含前瞻性声明。前瞻性声明提供了Novocure目前对未来事件的预期或预测。。

You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S.

您可以通过在声明中使用诸如“预期”、“估计”、“预期”、“项目”、“打算”、“计划”、“相信”或其他含义相似的词语和术语来识别其中一些前瞻性声明。。

Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law.

证券交易委员会。鉴于这些风险和不确定性，任何或所有这些前瞻性陈述可能被证明是不正确的。因此，您不应依赖任何此类因素或前瞻性陈述。此外，Novocure不打算公开更新任何前瞻性声明，除非法律要求。

Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion..

本文件中的任何前瞻性声明仅在本文件日期起生效。1995年的《私人证券诉讼改革法案》允许进行这种讨论。。